Krystal Biotech to Release Interim Clinical Update on KB407 from Highest Dose Cohort of CORAL-1 Study
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 21h ago
0mins
Source: NASDAQ.COM
- Clinical Progress: Krystal Biotech is set to release an interim clinical update on January 8, 2026, focusing on results from the highest dose cohort of the CORAL-1 study, which is expected to provide molecular assessments of KB407 transduction and CFTR protein expression, potentially offering new treatment hope for cystic fibrosis patients.
- Study Design: CORAL-1 is an open-label, dose escalation study designed to evaluate daily inhalation of 10 billion PFU of KB407, including up to three dose escalation cohorts, demonstrating the company's ongoing commitment to innovative therapies for adult cystic fibrosis patients.
- Market Potential: With approximately 40,000 cystic fibrosis patients in the U.S. and an estimated 105,000 diagnosed globally, the demand for KB407 highlights significant market potential, and successful outcomes could substantially enhance Krystal Biotech's position in this therapeutic area.
- Financial Performance: In Q3 2025, Krystal reported $97.8 million in net product revenue from VYJUVEK, up from $83.84 million year-over-year, indicating strong commercialization progress in gene therapy and enhancing the attractiveness of its R&D pipeline.
Analyst Views on KRYS
Wall Street analysts forecast KRYS stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for KRYS is 221.00 USD with a low forecast of 198.00 USD and a high forecast of 255.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
9 Buy
1 Hold
0 Sell
Strong Buy
Current: 246.370
Low
198.00
Averages
221.00
High
255.00
Current: 246.370
Low
198.00
Averages
221.00
High
255.00
About KRYS
Krystal Biotech, Inc. is an integrated, commercial-stage biotechnology company. The Company is focused on the discovery, development, and commercialization of genetic medicines to treat diseases with high unmet medical needs. Its product candidates in various stages of clinical and preclinical development include KB407, KB408, KB707, KB105, KB801, KB803, KB304 and KB301. Its commercial product, VYJUVEK, is a redosable gene therapy, and a genetic medicine approved in the United States and Europe for the treatment of dystrophic epidermolysis bullosa. KB407 is being developed for the treatment of Cystic Fibrosis. KB408 is being developed for the treatment of Alpha-1 Antitrypsin Deficiency, a rare lung disease. KB707 is being developed for the treatment of solid tumors. KB105 is being developed for TGM1-Deficient Autosomal Recessive Congenital Ichthyosis. KB803 is a redosable eye drop formulation of B-VEC, designed for the treatment of ocular complications.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
